Twitter | Search | |
Search Refresh
Delgoffe Lab 2h
Tomorrow I’ll be talking about metabolic barriers to cancer during an Webinar Series about immunometabolism and cancer! Lots of exciting talks planned. Come check it out! 11-2 tomorrow!
Reply Retweet Like
Jay Allen May 26
Sarah from Sydney has had tough times with including tumours in neck, right arm, spleen, ovaries, left tibia. BUT! treatment Ipilimumab/Nivolumab HAS WORKED! Latest scan results ALL CLEAR!!! and it’s Sarah’s birthday today! Happiest 28th birthday mate! 💐
Reply Retweet Like
Dinesh Rakheja May 25
Replying to @dinesh_rakheja
CD43 upfront may not be that useful🤔(unless it becomes important for - ), but once you have a "CD43-only" phenotype in a round cell tumor, it strongly favors a neoplasm
Reply Retweet Like
Gil Morgan 19h
Just out📣 🇺🇸Approves nivolumab+ipilimumab🧪 Combo w/Limited as1️⃣st Line Treatment of Metastatic or Recurrent ‼️ This marks the6️⃣th indication for this combo across5️⃣types of ⚠️ ®-nivolumab
Reply Retweet Like
OWise May 26
Two identified biomarkers could predict immunotherapy response in : an increase in PD-L1 expression in both tumour and immune cells, and an increase in the number of PD-L1 genes could be associated with benefits.
Reply Retweet Like
Immunometabolism Network May 21
Lactate-rich environment can impede immune cell functions. Nice article that brings this to attention: The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
Reply Retweet Like
Journal of Cancer Research and Immuno-Oncology May 24
High doses of 60 plus-year-old chemo drug found to spur immune system attack on . , a mainstay of chemotherapy for many cancers, acts as both chemotherapy and at high doses, study finds.
Reply Retweet Like
Catch Me If You Cancer May 26
Reply Retweet Like
Anirban Maitra May 25
From et al: Early signal using a combination regimen of BL-8040 (CXCR4 peptidomimetic antagonist) + aPD-1 in heavily pre-treated (typically no signal with IO). The correlatives are important 👇🏾
Reply Retweet Like
Asaf Madi 17h
Happy to be part of the most widely read papers of 2019, annual Best of series to showcase some of this past year's most exciting immunology research. exhaustion and
Reply Retweet Like
Chiles Research Inst May 26
Congrats to and colleagues for their article in the latest from | NKTR-214 synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. Read more >>
Reply Retweet Like
pvukovic May 24
Excellent talk by prof. Peter Schmid on in early highlighting open questions for neoadjuvant chemo+anti-PDL1/PD1 and new directions
Reply Retweet Like
Tariq Daouda, PhD May 26
, the website of our AI for COVID-19 vaccine is now available in Spanish and Portuguese! The '.world' makes even more sense now.
Reply Retweet Like
Kelvin Bao, FRCR May 24
is anything but a single disease entity! Treatment should be diversified accordingly.
Reply Retweet Like
Edna Cukierman May 22
Amid CAFs (S1 clusters), ECM-myCAF and TGFb-myCAF, are correlated with an CAFs, whereas detox-iCAF and IL-iCAF are not! Single-cell Analysis Reveals Clusters Linked to in Cancer
Reply Retweet Like
Omid Hamid MD May 26
Reply Retweet Like
Poul Sørensen May 25
Looking forward to attend and present at the upcoming EAACI Digital Congress 2020 June 6-8
Reply Retweet Like
Ovarian Cancer Action May 25
Immunotherapy turns the body’s immune system against cancer. uses drugs to target tumours but healthy cells are affected. boosts the immune system, enabling it to recognise & eliminate cancer cells, leaving healthy cells alone:
Reply Retweet Like
R. Bryan Bell, MD, DDS, FACS 22h
Reply Retweet Like
vdM_Lab 8h
Exciting new work from our lab now out in ! We investigated the role of in load-induced . Great work by and collaboration with
Reply Retweet Like